dc.contributor.author
Dilger, Hansjörg
dc.contributor.author
Leissner, Linn
dc.contributor.author
Bosanska, Lenka
dc.contributor.author
Lampe, Christina
dc.contributor.author
Plöckinger, Ursula
dc.date.accessioned
2018-06-08T03:45:49Z
dc.date.available
2014-01-08T10:58:01.956Z
dc.identifier.uri
https://refubium.fu-berlin.de/handle/fub188/15878
dc.identifier.uri
http://dx.doi.org/10.17169/refubium-20065
dc.description.abstract
Introduction: Mucopolysaccharidosis VI (MPS VI) is an inherited lysosomal
storage disease caused by a mutation of the gene for arylsulfatase B (ASB). Of
the thirty-one patients registered in Germany, almost fifty percent have a
Turkish migration background. MPS VI is treated by enzyme replacement therapy
(ERT), which is time-consuming and expensive. Methods: This interdisciplinary
study explored the illness perceptions and clinical treatment experiences
among ten MPS VI patients with a Turkish migration background in two centers
for metabolic diseases (Berlin and Mainz, Germany). The clinical treatment
situation was observed and semi-structured interviews were conducted with
patients and health care personnel, in addition to participatory observation
in four patients’ everyday environments in Berlin. The data from the
interviews, patient records, and personal field notes were encoded, cross-
related, and analyzed. Results: Patients’ acknowledgement of the disease and
coping strategies are influenced predominantly by the perception of their
individual health status and the handling of the disease within their family.
Patients’ willingness to cooperate with treatment strategies is further
modified by their knowledge of the disease and the relationships with their
health care providers. In this analysis, cultural factors turned out to be
marginally relevant. Conclusion: As with other chronic and debilitating
diseases, effective treatment strategies have to reach beyond delivering
medication. Health care providers need to strengthen the support for patients
with a migration background. In this regard, they should respect the patients’
cultural and social background and their personal perception of the disease
and the therapy. Yet structural and social aspects (clinical setting, family
and educational background) may be more crucial here than ‘‘cultural
barriers.’’
en
dc.rights.uri
http://creativecommons.org/licenses/by/3.0/
dc.subject.ddc
600 Technik, Medizin, angewandte Wissenschaften
dc.subject.ddc
300 Sozialwissenschaften
dc.title
Illness Perception and Clinical Treatment Experiences in Patients with M.
Maroteaux-Lamy (Mucopolysaccharidosis Type VI) and a Turkish Migration
Background in Germany
dc.type
Wissenschaftlicher Artikel
dcterms.bibliographicCitation
Plos One ; Vol. 8. 2013, Issue 6
dcterms.bibliographicCitation.doi
10.1371/journal.pone.0066804
dcterms.bibliographicCitation.url
http://dx.doi.org/10.1371/journal.pone.0066804
refubium.affiliation
Politik- und Sozialwissenschaften
de
refubium.affiliation.other
Institut für Sozial- und Kulturanthropologie / Arbeitsstelle Medizinethnologie
refubium.funding
Deutsche Forschungsgemeinschaft (DFG)
refubium.mycore.fudocsId
FUDOCS_document_000000019233
refubium.note.author
Gefördert durch die DFG und den Open Access Publikationsfonds der Freien
Universität Berlin.
refubium.resourceType.isindependentpub
no
refubium.mycore.derivateId
FUDOCS_derivate_000000002851
dcterms.accessRights.openaire
open access